Leaders in next-generation targeted protein degrader design and development
Degrading proteins.
Saving lives.
About Us ++ Overview
Biotheryx is advancing a portfolio of first-in-class protein degraders, with an initial focus on validated targets in cancer and inflammatory disease.
Our Science ++ Overview
Our PRODEGY (Protein Degrader Technology) platform was designed as a new and powerful targeted protein degradation drug discovery engine. Our platform was built on our expertise in modulating Cereblon and includes proprietary solutions and unique tools for targeted protein degrader (TPD) drug design.
Uniquely modulating Cereblon to control its function in ways no-one has ever done before
Pipeline ++ Overview
Leveraging our PRODEGY platform, we are building a pipeline of first-in-class protein degraders, including molecular glues and bifunctional degraders, with an initial focus in oncology and inflammatory disorders.
A pipeline of first-in-class protein degraders with potential to transform patient treatment
News ++ Press Releases
July 17, 2024 | Biotheryx
Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with Fulvestrant for HR+/HER2- Breast Cancer
SAN DIEGO, CA. July 17, 2024 — Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders[…] Read More
May 7, 2024 | Biotheryx
Biotheryx Announces U.S. FDA Clearance of Investigational New Drug Application for BTX-9341, a First-In-Class, Dual Bifunctional Degrader of CDK4/6
SAN DIEGO, CA. May 7, 2024 — Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein[…] Read More
May 25, 2023 | Biotheryx
Biotheryx to Present New Preclinical Data on Bifunctional Degraders for CDK4/6 and SOS1 at 2023 ASCO Annual Meeting
BTX-9341 demonstrated potent degradation of CDK4/6 and tumor growth regression in resistant cells in preclinical breast cancer models, along with[…] Read More
April 17, 2023 | Biotheryx
Biotheryx Presents Preclinical CDK4/6 and SOS1 Protein Degrader Data at AACR 2023 Annual Meeting
Data for CDK4/6 and SOS1 programs highlight differentiated therapeutic profiles BTX-9341 nominated as development candidate for CDK4/6 degrader program for[…] Read More
April 5, 2023 | Biotheryx
Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets
Collaboration will leverage Biotheryx’s PRODEGY platform to discover molecular glue degraders for multiple historically undruggable novel oncology targets Biotheryx to[…] Read More
February 15, 2023 | Biotheryx
Biotheryx to Participate in Wells Fargo 2023 Targeted Protein Degradation Virtual Summit
SAN DIEGO, CA. February 15, 2023 — Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative[…] Read More
October 24, 2022 | Biotheryx
Biotheryx to Present Preclinical Findings on Protein Degrader Programs at 5th Annual Targeted Protein Degradation Summit
Data from degrader program targeting SOS1 for KRAS mutant cancers to be presented in keynote plenary session Latest preclinical data[…] Read More
August 24, 2022 | Biotheryx
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Ms. Lawhon has nearly 20 years of oncology drug development, partner engagement and corporate strategy leadership experience SAN DIEGO, CA.[…] Read More
May 26, 2022 | Biotheryx
Biotheryx to Present Preclinical Data for Its Dual Protein Degrader BTX-1188 at the 2022 American Society of Clinical Oncology Annual Meeting
BTX-1188 Showed Deep and Durable Dual Degradation of GSPT1 and IKZF1/3 In Vitro Along with Beneficial Immunomodulatory Properties Data Support[…] Read More
April 25, 2022 | Biotheryx
Biotheryx Announces Appointment of Jeff Caravella as Chief Financial Officer
Mr. Caravella has more than 20 years of healthcare finance experience, including at Tango Therapeutics and Johnson & Johnson SAN[…] Read More
February 23, 2022 | Biotheryx
BioTheryX Appoints Nancy Miller-Rich as Chair of Its Board of Directors
Ms. Miller-Rich brings over 35 years of biopharma leadership experience, including senior roles at Merck & Co. and Schering-Plough David[…] Read More
January 26, 2022 | Biotheryx
BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188
Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of BTX-1188 in Patients with Advanced Hematologic and Solid Tumor Malignancies[…] Read More
January 20, 2022 | Biotheryx
BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer
SAN DIEGO, Jan. 20, 2022 — BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving medicines,[…] Read More
November 2, 2021 | Biotheryx
BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies
Enrollment for Phase 1 Clinical Trial to Commence by End of 2021 SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — BioTheryX,[…] Read More
October 28, 2021 | Biotheryx
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
SAN DIEGO, Oct. 28, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving[…] Read More
August 6, 2021 | Biotheryx
BioTheryX Announces Appointments of Three New Members to its Board of Directors
SAN DIEGO, Aug. 6, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on creating life-saving medicines through targeted protein[…] Read More
June 9, 2021 | Biotheryx
BioTheryX Announces First Patient Dosed with BTX-A51 in Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
SAN DIEGO, June 9, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More
May 25, 2021 | Biotheryx
BioTheryX to Present at the 2021 Jefferies Virtual Healthcare Conference
SAN DIEGO, May 25, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More
May 20, 2021 | Biotheryx
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
First molecular glue program, BTX-1188, expected to enter the clinic by the end of 2021 Additional protein degradation programs on[…] Read More
May 18, 2021 | Biotheryx
BioTheryX Announces Expansion of Scientific Advisory Board with Appointment of Brenda Schulman
SAN DIEGO, May 18, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More
May 4, 2021 | Biotheryx
BioTheryX to Present at 2021 RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 4, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More
April 7, 2021 | Biotheryx
BioTheryX Announces Expansion of Scientific Advisory Board
SAN DIEGO, April 7, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More
March 3, 2021 | Biotheryx
BioTheryX to Present at the Barclays Global Healthcare Conference and the Credit Suisse Solebury Trout Healthcare Innovators Conference
SAN DIEGO, March 3, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More
February 15, 2021 | Biotheryx
BioTheryX to Participate in Upcoming Scientific and Investor Events
SAN DIEGO, Feb. 15, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today[…] Read More
February 1, 2021 | Biotheryx
BioTheryX Appoints Jamie Donadio as Chief Financial Officer
SAN DIEGO, Jan. 7, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More
January 7, 2021 | Biotheryx
BioTheryX Appoints Robert F. Williamson, III as President and Chief Executive Officer
SAN DIEGO, Jan. 7, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More
July 28, 2020 | Biotheryx
BioTheryX Announces $35 Million Series D Financing
SAN DIEGO, CA, July 28, 2020 — BioTheryX, Inc., a clinical stage biotechnology company harnessing the power of protein modulation[…] Read More
March 6, 2020 | Biotheryx
BioTheryX, Inc. Announces the Appointment of Professor Yinon Ben- Neriah, M.D., Ph.D., to its Scientific Advisory Board
Accomplished scientist who created BioTheryX’s promising lead clinical candidate targeting AML adds significant expertise in oncology & immunology to distinguished[…] Read More
January 16, 2020 | Biotheryx
BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51
Study is evaluating the safety/tolerability of BTX-A51 in patients with relapsed/refractory acute myeloid leukemia (AML), as well as high risk[…] Read More
November 11, 2019 | Biotheryx
BioTheryX, Inc. Announces the Appointment of BioPharma Finance Veteran Peter N. Crnkovich to Board of Directors
Part of BioTheryX’s previously announced plan to continue building out its Board of Directors with key industry leaders now that[…] Read More
September 18, 2019 | Biotheryx
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
BioTheryX plans to continue building out Board of Directors with key biopharma industry leaders as Company transitions from preclinical to[…] Read More
May 29, 2019 | Biotheryx
BioTheryX Announces FDA Approval of IND Application to Initiate Phase 1 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia
Expect Enrollment of Phase 1 Trial to Begin in the Third Quarter of 2019 CHAPPAQUA, N.Y., May 29, 2019 /PRNewswire/[…] Read More
August 26, 2018 | Biotheryx
A promising cure for acute leukemia may be within reach
Israel 21c, August 26, 2018 Read Story
August 24, 2018 | Biotheryx
For first time in 40 years, cure for acute leukemia within reach
EurekAlert, AAAS, August 24, 2018 Read Story
September 8, 2016 | Biotheryx
BioRap and BioTheryX Sign Strategic Collaborative Agreement for the Development of Novel Protein Degradation Compounds for the Treatment of Cancer and Immune Disorder
CHAPPAQUA, N.Y., Sept. 08, 2006 /PRNewswire/ — BioTheryX, Inc. (BTX), is developing next-generation drugs that selectively regulate the stability of[…] Read More
May 4, 2016 | Biotheryx
Yissum and BioTheryX Sign Licensing Agreement for the Development of Next-Generation Protein Degradation and Immunomodulatory Treatment for Hematological Cancers
CHAPPAQUA, N.Y., May 04, 2016 /PRNewswire/ — Yissum Research Development Company of the Hebrew University of Jerusalem announced today that[…] Read More
November 30, 2010 | Biotheryx
The Leukemia & Lymphoma Society® Provides Equity Financing to BioTheryX, Inc. to Accelerate Drug Development for Blood Cancer
WHITE PLAINS, N.Y. and CHAPPAQUA, N.Y., Nov. 30, 2010 /PRNewswire/ — The Leukemia & Lymphoma Society (LLS) and BioTheryX, Inc.[…] Read More
Contact Us ++ Address
5871 Oberlin Drive
Suite 100
San Diego, CA 92121
[email protected]
